A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease

Neurology

Volumn 47, Issue 6, 1996, Pages 1389-1395

  Thal, L J ^a   Schwartz, G ^b   Sano, M ^c   Weiner, M ^d   Knopman, D ^e   Harrell, L ^f   Bodenheimer, S ^b   Rossor, M ^g   Philpot, M ^h   Schor, J ^b   Goldberg, A ⁱ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

^c Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e University at Minnesota   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^h KING'S COLLEGE LONDON   (United Kingdom)

ⁱ Pharmax Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; PHYSOSTIGMINE SALICYLATE;

ADULT; AGED; ALZHEIMER DISEASE; ANOREXIA; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SINGLE BLIND PROCEDURE; SUSTAINED DRUG RELEASE; VOMITING;

EID: 10544220019     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.6.1389     Document Type: Article

References (23)

1. Bartus RT, Johnson HR. Short-term memory in the rhesus monkey: disruption from the anticholinergic scopolamine. Pharmacol Biochem Behav 1976;5:39-40.
2. Drachman D, Leavitt J. Human memory and the cholinergic system: a relation to aging? Arch Neurol 1974;30:113-121.
3. Perry E, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978;2:1457-1459.
4. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, DeLong MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982;215:1237-1239.
5. Koelle G. Anticholinesterase agents. In: Goodman LS, Gilman A, eds. The pharmacologic basis of therapeutics. 5th ed. New York; Macmillan Publishing Co, 1975:445-466.
6. Bartus RT. Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: effects of concurrent administration of physostigmine and methylphenidate with scopolamine. Pharmacol Biochem Behav 1978;9:833-836.
7. Thal LJ, Masur DM, Blau AD, Fuld PA, Klauber MR. Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease. J Am Geriatr Soc 1989;37:42-48.
8. Mohs RC, Davis BM, Johns CA, et al. Oral physostigmine treatment of patients with Alzheimer's disease. Am J Psychiatry 1985;142:28-33.
9. Beller SA, Overall JE, Swann AE. Efficacy of oral physostigmine in primary degenerative dementia. Psychopharmacology 1985;87:147-151.
10. Stern Y, Sano M, Mayeux R. Effect of oral physostigmine in Alzheimer's disease. Ann Neurol 1987;220:306-310.
11. Davis KL, Thal LJ, Gamzu ER, et al. Tacrine in patients with Alzheimer's disease: a double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992;327:1253-1259.
12. Farlow M, Gracon ST, Hershey LA, Lewis KW, Sadowsky GH, Dolan-Urene J. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992;268:2523-2529.
13. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis ES, Gracon SI, for the Tacrine Study Group. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-991.
14. Thal LJ, Lasker B, Sharpless NS, Bobotas G, Schor JM, Nigalye A. Plasma physostigmine concentrations after controlled-release oral administration. Arch Neurol 1989;46:13.
15. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Standlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
16. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading on the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
17. Rosen WG, Terry RD, Fuld PA, et al. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980;7:486-488.
18. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
19. Clinical global impressions. In: Guy W, ed. ECDEU assessment manual for psychopharmacology. Rev. ed. Rockville, MD: Department of Health, Education and Welfare, 1976: 218-222. (DHEW publication no [ADM] 76-338.)
20. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-186.
21. Kramer-Ginsberg E, Mohs RC, Aryan M, et al. Clinical predictors of course for Alzheimer's patients in a longitudinal study: a preliminary report. Psychopharm Bull 1988;24:458-462.
22. Perry EK, Haroutunian V, Davis KL, Levy R. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport 1994;5:747-749.
23. Poirier J, Delisle MC, Quirion R. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease. Proc Natl Acad Sci USA 1995;92:12260-12264.